TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26718897

Group type: EXPERIMENTAL
Intervention: Community-based educational intervention led by lay health workers including monthly distribution of Iron and folic acid (IFA) supplements and five monthly counseling sessions.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual (control group) including distribution of IFA to mothers of anemic children without education and counseling support.
Number of subjects: 60
Study: 24077193

Group type: EXPERIMENTAL
Intervention: Cervical epidural injections with lidocaine 0.5% preservative-free, 5 mL (Group I)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cervical epidural injections with 0.5% preservative-free lidocaine mixed with 1 mL or 6 mg of non-particulate betamethasone (Group II)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cervical epidural injections with lidocaine 0.5% preservative-free (Group I)
Number of subjects: 120
Study: 21180682

Group type: EXPERIMENTAL
Intervention: Inion GTR Biodegradable Membrane System barrier without any graft
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bio-Oss (100% loosely packed granular)
Number of subjects: 10
Study: 19067478

Group type: EXPERIMENTAL
Intervention: Peer-led sex education
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Control (teacher-led sex education)
Number of subjects: 9000
Study: 21029654

Group type: EXPERIMENTAL
Intervention: 64 multislice CT at 80 kV
Number of subjects: 120

Group type: COMPARATOR
Intervention: 64 multislice CT at 100 kV
Number of subjects: 120

Group type: COMPARATOR
Intervention: Echocardiography with Doppler
Number of subjects: 120
Study: 15579575

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin A, C, and E regimen, supplemented orally for 2 months
Number of subjects: 18
Study: 12450708

Group type: EXPERIMENTAL
Intervention: Flt3 ligand (20 microg/kg, maximum 1500 microg) administered SQ every day for 1 week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Flt3 ligand (placebo control)
Number of subjects: 40
Study: 9883957

Group type: EXPERIMENTAL
Intervention: McKenzie management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-specific back massage and general back care advice (Control)
Number of subjects: 0
Study: 7976313

Group type: EXPERIMENTAL
Intervention: Type B tympanogram
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Tympanometry
Number of subjects: 370
Study: 2657199

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% with epinephrine 0.5% plus guanethidine 3%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epinephrine 0.5% plus guanethidine 3%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other glaucoma drugs
Number of subjects: 0
Study: 11961621

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted vaginal hysterectomy (LAVH)
Number of subjects: 48
Study: 29574905

Group type: EXPERIMENTAL
Intervention: Play-based psychosocial intervention
Number of subjects: 14
Study: 27502284

Group type: EXPERIMENTAL
Intervention: Breast Health Awareness program
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 370
Study: 25336703

Group type: EXPERIMENTAL
Intervention: Surgery only
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 637

Group type: EXPERIMENTAL
Intervention: Cisplatin ≤ 850 mg
Number of subjects: 637
Study: 22424162

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study: 20545874

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA) at 2 Hz-burst
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no electro-acupuncture)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 45
Study: 18569006

Group type: EXPERIMENTAL
Intervention: 3.0 g NS day(‐1) (high dose, HD)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: 1.5 g NS day(‐1) (low dose, LD)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 177
Study: 16222401

Group type: EXPERIMENTAL
Intervention: D-hormone serum concentrations (high)
Number of subjects: 380

Group type: COMPARATOR
Intervention: D-hormone serum concentrations (low)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Calcium intake >= 512 mg/day
Number of subjects: 380

Group type: COMPARATOR
Intervention: Calcium intake < 512 mg/day
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: D-hormone serum concentrations
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Calcidiol serum levels
Number of subjects: 380
Study: 12610024

Group type: EXPERIMENTAL
Intervention: Diabetic Neuropathy Symptom (DNS) score
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Diabetic Neuropathy Examination (DNE) score
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 69
Study: 10496143

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg) administered at 13:00 hr for 5 consecutive days during the late follicular and early luteal phases of the menstrual cycle.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group (control)
Number of subjects: 0
Study: 7795515

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg atracurium
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.07 mg/kg vecuronium
Number of subjects: 40
Study: 2385209

Group type: EXPERIMENTAL
Intervention: 30 mg ASS daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: 300 mg ASS daily
Number of subjects: 20
Study: 6994760

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15
Study: 29974308

Group type: EXPERIMENTAL
Intervention: Self-exclusion measure (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control condition (no self-exclusion)
Number of subjects: 60
Study: 29953014

Group type: EXPERIMENTAL
Intervention: Ashwagandha extract (daily supplement for 42 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (daily supplement for 42 days)
Number of subjects: 0
Study: 27590106

Group type: EXPERIMENTAL
Intervention: Topical Dexamethasone (.5 mg/mL), rinsed with 5 mL for 5 minutes, 4 times a day, for 4 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Topical Tacrolimus (.5 mg/mL), rinsed with 5 mL for 5 minutes, 4 times a day, for 4 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Topical Dexamethasone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Topical Tacrolimus
Number of subjects: 46
Study: 24946627

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion group
Number of subjects: 145

Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 145

Group type: COMPARATOR
Intervention: Moxibustion group
Number of subjects: 145
Study: 23013731

Group type: EXPERIMENTAL
Intervention: PIK3CA mutation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: KRAS mutation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Endometrioid tumors
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Malignant mixed Mullerian tumors
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low-grade endometrioid cancers
Number of subjects: 150
Study: 20047770

Group type: COMPARATOR
Intervention: Usual Quality Improvement Program (UQIP)
Number of subjects: 2495

Group type: EXPERIMENTAL
Intervention: Advanced Quality Improvement Program (AQIP)
Number of subjects: 2495
Study: 16936007

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Glibenclamide + Nicorandil
Number of subjects: 240

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 240
Study: 16779202

Group type: EXPERIMENTAL
Intervention: ATHENA DSS with point-of-care feedback
Number of subjects: 0
Study: 12117085

Group type: EXPERIMENTAL
Intervention: T/APAP 75/650 mg (2 tablets)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HC/APAP (1 tablet)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: T/APAP 75/650 mg (1 tablet)
Number of subjects: 200
Study: 11332162

Group type: EXPERIMENTAL
Intervention: Colicky infants (HRV analysis)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control infants (HRV analysis)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups (HRV analysis)
Number of subjects: 12
Study: 10387366

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7518766

Group type: EXPERIMENTAL
Intervention: Intravenous or intramuscular ceftriaxone 50 mg/kg/day for 2 days followed by oral cefetamet pivoxil 20 mg/kg/day in 2 divided doses to complete 7 days of treatment (arm A)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Ceftriaxone 50 mg/kg/day for 1 day followed by 6 days' treatment with cefetamet pivoxil 20 mg/kg/day (arm B)
Number of subjects: 118
Study: 2923962

Group type: COMPARATOR
Intervention: 4 x 10 mg test tablets, 1 x 40 mg test tablet, 4 x 10 mg Inderal tablets, 40 mg of propranolol HCl in solution (Study I)
Number of subjects: 48

Group type: COMPARATOR
Intervention: 1 x 80 mg test tablet, 1 x 80 mg Inderal tablet, 80 mg of propranolol HCl in solution (Study II)
Number of subjects: 48
Study: 824929

Group type: EXPERIMENTAL
Intervention: ICI 74.917 aerosol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Disodium cromoglycate powder
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31736394

Group type: EXPERIMENTAL
Intervention: Arabin's pessary and vaginal micronized progesterone (Group A, n=60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vaginal micronized progesterone only (Group B, n=60)
Number of subjects: 120
Study: 31212044

Group type: EXPERIMENTAL
Intervention: Specific balance rehabilitation exercises
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inpatient therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Using a walking aid
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Low baseline BBS score
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Specific treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: pMS vs. relapsing-remitting MS
Number of subjects: 150
Study: 31593484

Group type: EXPERIMENTAL
Intervention: FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, and fluorouracil bolus 400 mg/m2 on day 1, fluorouracil infusion 2,400 mg/m2 for 46 hours)
Number of subjects: 321

Group type: COMPARATOR
Intervention: FL (fluorouracil 380 mg/m2 and leucovorin 20 mg/m2)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 321

Group type: COMPARATOR
Intervention: FL
Number of subjects: 321
Study: 28486344

Group type: EXPERIMENTAL
Intervention: Chronic diseases
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Multimorbidity
Number of subjects: 516
Study: 25218876

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (100 mL before each dialysis session)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (1,050 mg daily)
Number of subjects: 24
Study: 24106787

Group type: EXPERIMENTAL
Intervention: Structured transition program (multidisciplinary, complex intervention)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Structured transition program
Number of subjects: 188
Study: 21793817

Group type: EXPERIMENTAL
Intervention: Nontraditional practice (problems presented in a nontraditional format, e.g., 17 = 9 + 8)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional practice (problems presented in the traditional 'operations on left side' format, e.g., 9 + 8 = 17)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No extra practice
Number of subjects: 90
Study: 19262008

Group type: EXPERIMENTAL
Intervention: Topical steroids
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 21
Study: 16738028

Group type: EXPERIMENTAL
Intervention: Self-anchoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-stereotyping
Number of subjects: 0
Study: 15305956

Group type: EXPERIMENTAL
Intervention: Short nitroglycerine test (15 minutes passive phase + 400 microg sublingual nitroglycerin for 15 minutes)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional isoproterenol protocol (30 minutes passive phase + 20 minutes drug-challenge phase)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Short nitroglycerine test
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional isoproterenol protocol
Number of subjects: 128
Study: 11165450

Group type: EXPERIMENTAL
Intervention: Active outreach with $5 per visit incentive (Condition 1)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Active outreach without monetary incentive (Condition 2)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Active outreach at study community site with $5 per visit incentive (Condition 3)
Number of subjects: 163
Study: 9410508

Group type: EXPERIMENTAL
Intervention: Muscle strength and coordination training program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Light physical exercise (Control)
Number of subjects: 0
Study: 8437633

Group type: EXPERIMENTAL
Intervention: HA-1A (Centoxin), a human anti-endotoxin monoclonal IgM antibody
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3728506

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 179

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Tobramycin with liver disease
Number of subjects: 179

Group type: COMPARATOR
Intervention: Cefotaxime with liver disease
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Tobramycin without liver disease
Number of subjects: 179
Study: 30376366

Group type: EXPERIMENTAL
Intervention: Exercise training (2×60 minute supervised sessions per week)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care and Exercise training
Number of subjects: 28
Study: 30157880

Group type: EXPERIMENTAL
Intervention: Anakinra, self-administered daily by subcutaneous injection over 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 27125363

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir plus lamivudine (dual-therapy)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir plus two NRTIs (triple-therapy)
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir plus lamivudine (dual-therapy) with discontinuation of tenofovir-DF
Number of subjects: 239

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir plus two NRTIs (triple-therapy) with discontinuation of abacavir
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir plus lamivudine (dual-therapy) and Lopinavir/ritonavir plus two NRTIs (triple-therapy)
Number of subjects: 239
Study: 24915904

Group type: EXPERIMENTAL
Intervention: Health insurance based case management programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study: 23075176

Group type: EXPERIMENTAL
Intervention: Risperidone continued for 32 weeks (group 1)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Risperidone for 16 weeks followed by placebo for 16 weeks (group 2)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo for 32 weeks (group 3)
Number of subjects: 110
Study: 20398185

Group type: EXPERIMENTAL
Intervention: Reduced blood sampling schedule for children
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard blood sampling schedule
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: PK measurements for dose tailoring of FVIII
Number of subjects: 152
Study: 16835823

Group type: EXPERIMENTAL
Intervention: Intensified Training (IT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal Training (NT)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 15923803

Group type: EXPERIMENTAL
Intervention: Mastectomy (MT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Breast-conserving therapy (BCT)
Number of subjects: 6
Study: 12884068

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 239

Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 239
Study: 10475187

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusions of L-arginine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusions of sodium nitroprusside
Number of subjects: 0
Study: 8864503

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infra-red thermography
Number of subjects: 0
Study: 1926024

Group type: EXPERIMENTAL
Intervention: Care of a respiratory health worker
Number of subjects: 152

Group type: COMPARATOR
Intervention: Normal services provided by the outpatient department
Number of subjects: 152
Study: 6353842

Group type: EXPERIMENTAL
Intervention: Lens implantation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Extended-wear contact lenses
Number of subjects: 61
Study: 4002834

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 18
Study: 31987545

Group type: EXPERIMENTAL
Intervention: Training with the custom-made visual feedback device
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (routine activities)
Number of subjects: 34
Study: 29761274

Group type: EXPERIMENTAL
Intervention: Low intra-abdominal pressure (8 mmHg) with deep-block (post-tetanic count 1-2)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Standard intra-abdominal pressure (12 mmHg) with deep-block
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Standard intra-abdominal pressure (12 mmHg) with moderate-block (train-of-four count 1-2)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Low intra-abdominal pressure (8 mmHg)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Standard intra-abdominal pressure (12 mmHg)
Number of subjects: 131
Study: 27633636

Group type: EXPERIMENTAL
Intervention: Family-led rehabilitation intervention for stroke patients, details on dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed methods including semistructured interviews and quantitative process data analysis.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost data analysis from patients and families perspective.
Number of subjects: 0
Study: 25056464

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone (group A, n=51)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Micronized vaginal progesterone (group B, n=50)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Pregnant women without history of recurrent miscarriage (group C, n=32)
Number of subjects: 133
Study: 22772417

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation management (treatment group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no rehabilitation management)
Number of subjects: 56
Study: 20117625

Group type: EXPERIMENTAL
Intervention: Arthroscopic debridement and synovectomy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nonoperative therapy (control)
Number of subjects: 23
Study: 17955571

Group type: EXPERIMENTAL
Intervention: Single-voxel 1H MRS (SV-MRS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Spectroscopic imaging (MRSI)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MRSI
Number of subjects: 10

Group type: COMPARATOR
Intervention: MRSI vs SV-MRS
Number of subjects: 10
Study: 16836502

Group type: EXPERIMENTAL
Intervention: Synergized pyrethrins foam (PF) for 3 days
Number of subjects: 240

Group type: COMPARATOR
Intervention: Benzyl benzoate (BB) lotion for 5 days
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Tolerability score for PF
Number of subjects: 240

Group type: COMPARATOR
Intervention: Tolerability score for BB
Number of subjects: 240
Study: 11261827

Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 60 mgs/day
Number of subjects: 217

Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 40 mgs/day
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Toremifene (TOR)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) and Tamoxifen (TAM)
Number of subjects: 217
Study: 9557098

Group type: EXPERIMENTAL
Intervention: Podophyllin 0.5% in ethanol (PE)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Podophyllin 0.25% in ethanol (PE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Podophyllin 25% in tincture benzoin (PB)
Number of subjects: 35
Study: 8002875

Group type: COMPARATOR
Intervention: Dietary intervention
Number of subjects: 17460

Group type: COMPARATOR
Intervention: Dietary intervention with effective cholesterol lowering
Number of subjects: 17460

Group type: COMPARATOR
Intervention: Dietary intervention in angiographic trials
Number of subjects: 17460

Group type: COMPARATOR
Intervention: Fish oil after coronary angioplasty
Number of subjects: 17460
Study: 2702160

Group type: EXPERIMENTAL
Intervention: Behavioral therapy by dental school assistants (experimental group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional methods by students (control group)
Number of subjects: 50
Study: 4311188

Group type: EXPERIMENTAL
Intervention: Intravenous methylamphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral dexamphetamine
Number of subjects: 0
Study: 30223381

Group type: EXPERIMENTAL
Intervention: Continuous ultrasound treatment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound treatment
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham ultrasound treatment
Number of subjects: 54
Study: 27385192

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24982002

Group type: EXPERIMENTAL
Intervention: Balance and stability-focused rehabilitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular physiotherapy
Number of subjects: 50
Study: 22269538

Group type: EXPERIMENTAL
Intervention: Non-evaluative performance feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback (Control)
Number of subjects: 0
Study: 19857039

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (radiotherapy or radiochemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study: 18598323

Group type: EXPERIMENTAL
Intervention: CABG roller pump CPB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CABG centrifugal vortex pump CPB
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Heart valve surgery roller pump CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 30